Epidemic control with endogenous treatment capability under popular discontent and social fatigue
研究在民众不满和社会疲劳背景下，比较三种非治疗性干预政策（出行限制、保障社交互动及两者结合）的成本效益，发现加速疫情高峰的策略优于传统延迟高峰策略，且社会疲劳对成本影响小但会放大感染峰值。
This paper investigates how the optimization of policymaker interventions against an epidemic disease is affected by contextual factors related to (i) a cost‐centered approach to countering the epidemic, (ii) eventual correlative popular discontent, and (iii) growing social fatigue engendered by nontherapeutic interventions. Three nontherapeutic policies—mobility restrictions (MR), securing social interactions (SSI), and a combination of both (MR + SSI)—are compared in terms of effectiveness and efficiency in preventing infections and saving lives. The costs associated with these policies are economic as well as operational. The objective is to select the lowest cost policy that is the least sensitive to the cited contextual factors. In many ways, our model applies to the Covid‐19 pandemic in its prevaccine phase. Our study shows the significant influence of popular discontent on epidemic control policies. We show that in contrast to the standard delayed peak strategy, which seeks to delay and flatten the epidemic peak, there is an alternative strategy, counter to conventional wisdom, which consists of accelerating the onset of the epidemic peak. Although the delayed peak strategy is contingent on popular neutrality, the advanced peak strategy results from popular discontent as a corollary of a cost‐centered approach. We also find that social fatigue does not affect the social cost much but, in contrast to the controlled scenarios without social fatigue, it amplifies the peak of infections. In this context, the inclusive policy that incorporates MR + SSI mitigates the negative impact of social fatigue, although it comes at the cost of tighter restrictions than either of the exclusive policies. We conclude that, as opposed to popular discontent, social fatigue should be disregarded for the sake of greater effectiveness and efficiency in infection and death prevention. Our results can be used by policymakers to allocate resources appropriately in MR, SSI, or both and to build treatment capability.